DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB

DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB Stock

DE000VD39R63

Market Closed - Boerse Frankfurt Warrants 13:53:52 2024-06-14 EDT
36.49 ^EUR	+0.41%

Current month	+3.14%
1 month	-4.02%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	06-14	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	06-13	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	06-13	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	06-13	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-14	36.49	+0.41%
24-06-13	36.34	-1.20%
24-06-12	36.78	-1.47%
24-06-11	37.33	+1.47%
24-06-10	36.79	+2.91%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 01:53 pm

More quotes

Static data

Product type	Certificats Discount
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Vontobel
WKN	VD39R6
ISIN	DE000VD39R63
Date issued	2024-04-18
Cap	50 $
Last trading day	2025-03-21
Maturity	2025-03-21 (279 Days)
Parity	1 : 1
Emission price	40.42 €
Emission volume	N/A
Payment day	2025-03-28
Bonus	- €
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Discount (ask)	0.000000 %
Sideways yield	0.000000 %
Sideways yield pa	0.000000 %
Outperformance point	- $
Break even	0.000000 €
Highest since issue	40.82 €
Lowest since issue	34.82 €
Spread	0.06 €
Spread %	0.17%
Distance Cap	-8.8 $
Distance Cap %	-21.36%
Max. earning	-
Max. earning %	0.000000 %

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.2 USD

Average target price

53.19 USD

Spread / Average Target

+29.11%

Consensus